Cyclooxygenase inhibitors: From pharmacology to clinical read-outs

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1851, Issue 4, 2015, Pages 422-432

  Patrignani, Paola ^a   Patrono, Carlo ^b,c  

^a UNIVERSITY OF CHIETI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Aspirin; COX 1; COX 2; Coxib; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ENDOCANNABINOID; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; ISOENZYME;

ACETYLATION; ANALGESIC ACTIVITY; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR EFFECT; CHEMOPROPHYLAXIS; CLINICAL PHARMACOLOGY; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED RELEASE FORMULATION; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HUMAN; INFLAMMATION; METASTASIS POTENTIAL; NONHUMAN; PAIN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; SLOW RELEASE FORMULATION; STOMACH ACID SECRETION; THERAPY EFFECT; THROMBOCYTE ACTIVATION; THROMBOSIS; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GASTROINTESTINAL DISEASE; HEART DISEASES; METABOLISM; NEOPLASMS; RISK FACTOR; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICARCINOGENIC AGENTS; CARDIOVASCULAR AGENTS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL DISEASES; HEART DISEASES; HUMANS; INFLAMMATION; ISOENZYMES; MOLECULAR STRUCTURE; NEOPLASMS; RISK FACTORS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84922519182     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2014.09.016     Document Type: Review

References (123)

1. G. Born, and C. Patrono Antiplatelet drugs Br. J. Pharmacol. 147 2006 S241 S251
2. C. Patrono, and B. Rocca Nonsteroidal antiinflammatory drugs: past, present and future Pharmacol. Res. 59 2009 285 289
3. G.A. FitzGerald, and C. Patrono The coxibs, selective inhibitors of cyclooxygenase-2 N. Engl. J. Med. 345 2001 433 442
4. B.F. McAdam, F. Catella-Lawson, I.A. Mardini, S. Kapoor, J.A. Lawson, and G.A. FitzGerald Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 Proc. Natl. Acad. Sci. U. S. A. 96 1999 272 277
5. C. Patrono, L.A. García Rodríguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis N. Engl. J. Med. 353 2005 2373 2383
6. M.J. Thun, S.J. Henley, and C. Patrono Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues J. Natl. Cancer Inst. 94 2002 252 266
7. M.M. Wolfe, D.R. Lichtenstein, and G. Singh Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs N. Engl. J. Med. 340 1999 1888 1899
8. F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, R. Makuch, G. Eisen, N.M. Agrawal, W.F. Stenson, A.M. Burr, W.W. Zhao, J.D. Kent, J.B. Lefkowith, K.M. Verburg, and G.S. Geis Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 284 2000 1247 1255
9. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M. Bosi Ferraz, C.J. Hawkey, M.C. Hochberg, T.K. Kvien, T.J. Schnitzer for the VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N. Engl. J. Med. 343 2000 1520 1528
10. M.M. Bertagnolli, C.J. Eagle, A.G. Zauber, M. Redston, S.D. Solomon, K. Kim, J. Tang, R.B. Rosenstein, J. Wittes, D. Corle, T.M. Hess, G.M. Woloj, F. Boisserie, W.F. Anderson, J.L. Viner, D. Bagheri, J. Burn, D.C. Chung, T. Dewar, T.R. Foley, N. Hoffman, F. Macrae, R.E. Pruitt, J.R. Saltzman, B. Salzberg, T. Sylwestrowicz, G.B. Gordon, E.T. Hawk APC Study Investigators Celecoxib for the prevention of sporadic colorectal adenomas N. Engl. J. Med. 355 2006 873 884
11. J.A. Baron, R.S. Sandler, R.S. Bresalier, H. Quan, R. Riddell, A. Lanas, J.A. Bolognese, B. Oxenius, K. Horgan, S. Loftus, D.G. Morton APPROVe Trial Investigators A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas Gastroenterology 131 2006 1674 1682
12. P.M. Kearney, C. Baigent, J. Godwin, H. Halls, J.R. Emberson, and C. Patrono Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials BMJ 332 2006 1302 1308
13. Coxib and Traditional NSAID Trialists' (CNT) Collaboration N. Bhala, J. Emberson, A. Merhi, S. Abramson, N. Arber, J.A. Baron, C. Bombardier, C. Cannon, M.E. Farkouh, G.A. FitzGerald, P. Goss, H. Halls, E. Hawk, C. Hawkey, C. Hennekens, M. Hochberg, L.E. Holland, P.M. Kearney, L. Laine, A. Lanas, P. Lance, A. Laupacis, J. Oates, C. Patrono, T.J. Schnitzer, S. Solomon, P. Tugwell, K. Wilson, J. Wittes, and C. Baigent Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials Lancet 382 2013 769 779
14. M.L. Capone, S. Tacconelli, L. Di Francesco, A. Sacchetti, M.G. Sciulli, and P. Patrignani Pharmacodynamic of cyclooxygenase inhibitors in humans Prostaglandins Other Lipid Mediat. 82 2013 85 94
15. E.M. Smyth, T. Grosser, M. Wang, Y. Yu, and G.A. FitzGerald Prostanoids in health and disease J. Lipid Res. 50 2009 S423 S428
16. C.D. Funk Prostaglandins and leukotrienes: advances in eicosanoid biology Science 294 2001 1871 1875
17. S. Narumiya, and G.A. FitzGerald Genetic and pharmacological analysis of prostanoid receptor function J. Clin. Invest. 108 2001 25 30
18. R.M. Breyer, C.K. Bagdassarian, S.A. Myers, and M.D. Breyer Prostanoid receptors: subtypes and signaling Annu. Rev. Pharmacol. Toxicol. 41 2001 661 690
19. E. Ricciotti, and G.A. FitzGerald Prostaglandins and inflammation Arterioscler. Thromb. Vasc. Biol. 31 2011 986 1000
20. C.L. Bos, D.J. Richel, T. Ritsema, M.P. Peppelenbosch, and H.H. Versteeg Prostanoids and prostanoid receptors in signal transduction Int. J. Biochem. Cell Biol. 36 2004 1187 1205
21. K. Nagata, and H. Hirai The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes Prostaglandins Leukot. Essent. Fat. Acids 69 2003 169 177
22. H. Hirai, K. Tanaka, O. Yoshie, K. Ogawa, K. Kenmotsu, Y. Takamori, M. Ichimasa, K. Sugamura, M. Nakamura, S. Takano, and K. Nagata Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2 J. Exp. Med. 193 2001 255 261
23. N. Sawyer, E. Cauchon, A. Chateauneuf, R.P. Cruz, D.W. Nicholson, K.M. Metters, G.P. O'Neill, and F.G. Gervais Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2 Br. J. Pharmacol. 137 2002 1163 1172
24. L. Simmons, R.M. Botting, and T. Hla Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition Pharmacol. Rev. 56 2004 387 437
25. I. Kudo, and M. Murakami Prostaglandin E synthase: a terminal enzyme for prostaglandin E2 biosynthesis J. Biochem. Mol. Biol. 38 2005 633 638
26. M. Joo, and R.T. Sadikot PGD synthase and PGD2 in immune response Mediat. Inflamm. 2012 2012 1 6
27. W.L. Smith, D.L. DeWitt, and R.M. Garavito Cyclooxygenases: structural, cellular, and molecular biology Annu. Rev. Biochem. 69 2000 145 182
28. D.A. Dixon, C.D. Kaplan, T.M. McIntyre, G.A. Zimmerman, and S.M. Prescott Post-transcriptional control of cyclooxygenase-2 gene expression: the role of the 3-untranslated region J. Biol. Chem. 275 2000 11750 11757
29. C. Patrono, P. Patrignani, and L.A. García Rodríguez Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs J. Clin. Invest. 108 2001 7 13
30. V.B. O'Donnell Free radicals and lipid signalling in endothelial cells Antioxid. Redox Signal. 5 2003 195 203
31. T. Grosser, S. Fries, and G.A. FitzGerald Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities J. Clin. Invest. 116 2006 4 15
32. C.D. Loftin, H.F. Tiano, and R. Langenbach Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2 Prostaglandins Other Lipid Mediat. 68-69 2002 177 185
33. R. Langenbach, C. Loftin, C. Lee, and H. Tiano Cyclooxygenase knockout mice - models for elucidating isoform-specific functions Biochem. Pharmacol. 58 1999 1237 1246
34. Y. Yu, Y. Cheng, J. Fan, X.S. Chen, A. Klein-Szanto, G.A. FitzGerald, and C.D. Funk Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition J. Clin. Invest. 115 2005 986 995
35. H. Wang, H. Xie, X. Sun, P.J. Kingsley, L.J. Marnett, B.F. Cravatt, and S.K. Dey Differential regulation of endocannabinoid synthesis and degradation in the uterus during embryo implantation Prostaglandins Other Lipid Mediat. 83 2007 62 74
36. M.G. Sciulli, M.L. Capone, S. Tacconelli, and P. Patrignani The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain Pharmacol. Rep. 57S 2005 66 85
37. L.A. García Rodríguez, S. Tacconelli, and P. Patrignani Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population J. Am. Coll. Cardiol. 52 2008 1628 1636
38. E.L. Massó González, P. Patrignani, S. Tacconelli, and L.A. Rodríguez Variability of risk of upper gastrointestinal bleeding among nonsteroidal anti-inflammatory drugs Arthritis Rheum. 62 2010 1592 1601
39. S. Fries, T. Grosser, T.S. Price, J.A. Lawson, S. Kapoor, S. De Marco, M.T. Pletcher, T. Wiltshire, and G.A. FitzGerald Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2 Gastroenterology 130 2006 55 64
40. C.A. Rouzer, and L.J. Marnett Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways Chem. Rev. 111 2011 5899 5921
41. K.C. Duggan, D.J. Hermanson, J. Musee, J.J. Prusakiewicz, J.L. Scheib, B.D. Carter, S. Banerjee, J.A. Oates, and L.J. Marnett (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2 Nat. Chem. Biol. 7 2011 803 809
42. W. Neupert, R. Brugger, C. Euchenhofer, K. Brune, and G. Geisslinger Effects of ibuprofen enantiomers and its coenzyme A thioesters on human prostaglandin endoperoxide synthases Br. J. Pharmacol. 122 1997 487 492
43. C. Patrono, G. Ciabattoni, E. Pinca, F. Pugliese, G. Castrucci, A. De Salvo, M.A. Satta, and B.A. Peskar Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects Thromb. Res. 17 1980 317 327
44. P. Patrignani, M.R. Panara, A. Greco, O. Fusco, C. Natoli, S. Iacobelli, F. Cipollone, A. Ganci, C. Créminon, J. Maclouf, and C. Patrono Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases J. Pharmacol. Exp. Ther. 271 1994 1705 1712
45. M. Dovizio, A. Bruno, S. Tacconelli, and P. Patrignani Mode of action of aspirin as a chemopreventive agent Recent Results Cancer Res. 191 2013 39 65
46. C. Patrono Aspirin as an antiplatelet drug N. Engl. J. Med. 330 1994 1287 1294
47. M. Bala, C.N. Chin, A.T. Logan, T. Amin, L.J. Marnett, O. Boutaud, and J.A. Oates Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase Biochem. Pharmacol. 75 2008 1472 1481
48. P. Patrignani, P. Filabozzi, and C. Patrono Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects J. Clin. Invest. 69 1982 1366 1372
49. G.A. FitzGerald, J.A. Oates, J. Hawiger, R.L. Maas, L.J. Roberts 2nd, J.A. Lawson, and A.R. Brash Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man J. Clin. Invest. 71 1983 676 688
50. G.A. FitzGerald, A.R. Brash, P. Falardeau, and J.A. Oates Estimated rate of prostacyclin secretion into the circulation of normal man J. Clin. Invest. 68 1981 1272 1276
51. C. Patrono, G. Ciabattoni, F. Pugliese, A. Pierucci, I.A. Blair, and G.A. FitzGerald Estimated rate of thromboxane secretion into the circulation of normal humans J. Clin. Invest. 77 1986 590 594
52. G. Davì, and C. Patrono Platelet activation and atherothrombosis N. Engl. J. Med. 357 2007 2482 2494
53. I.A. Reilly, and G.A. FitzGerald Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs Blood 69 1987 180 186
54. F. Santilli, B. Rocca, R. De Cristofaro, S. Lattanzio, L. Pietrangelo, A. Habib, C. Pettinella, A. Recchiuti, E. Ferrante, G. Ciabattoni, G. Davì, and C. Patrono Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance" J. Am. Coll. Cardiol. 53 2009 667 677
55. M.L. Capone, S. Tacconelli, M.G. Sciulli, M. Grana, E. Ricciotti, P. Minuz, P. Di Gregorio, G. Merciaro, C. Patrono, and P. Patrignani Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects Circulation 109 2004 1468 1471
56. M.L. Capone, S. Tacconelli, M.G. Sciulli, P. Anzellotti, L. Di Francesco, G. Merciaro, P. Di Gregorio, and P. Patrignani Human pharmacology of naproxen sodium J. Pharmacol. Exp. Ther. 322 2007 453 460
57. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, A.J. Cucchiara, S. DeMarco, B. Tournier, S.N. Vyas, and G.A. FitzGerald Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N. Engl. J. Med. 345 2001 1809 1817
58. G. Renda, S. Tacconelli, M.L. Capone, D. Sacchetta, F. Santarelli, M.G. Sciulli, M. Zimarino, M. Grana, E. D'Amelio, M. Zurro, T.S. Price, C. Patrono, R. De Caterina, and P. Patrignani Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease Clin. Pharmacol. Ther. 80 2006 264 274
59. M.L. Capone, M.G. Sciulli, S. Tacconelli, M. Grana, E. Ricciotti, G. Renda, P. Di Gregorio, G. Merciaro, and P. Patrignani Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects J. Am. Coll. Cardiol. 45 2005 1295 1301
60. P. Anzellotti, M.L. Capone, A. Jeyam, S. Tacconelli, A. Bruno, P. Tontodonati, L. Di Francesco, L. Grossi, G. Renda, G. Merciaro, P. Di Gregorio, T.S. Price, L.A. García Rodríguez, and P. Patrignani Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences Arthritis Rheum. 63 2011 850 859
61. P. Patrignani, S. Tacconelli, E. Piazuelo, L. Di Francesco, M. Dovizio, C. Sostres, E. Marcantoni, P. Guillem-Llobat, M. Del Boccio, M. Zucchelli, C. Patrono, and A. Lanas Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action J. Thromb. Haemost. 12 2014 1320 1330
62. P. Patrignani, S. Tacconelli, and M.L. Capone Risk management profile of etoricoxib: an example of personalized medicine Ther. Clin. Risk Manag. 4 2008 983 997
63. L.J. Crofford, R.L. Wilder, A.P. Ristimaki, H. Sano, E.F. Remmers, H.R. Epps, and T. Hla Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids J. Clin. Invest. 93 1994 1095 1101
64. U. Schonbeck, G.K. Sukhova, P. Graber, S. Coulter, and P. Libby Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions Am. J. Pathol. 155 1999 1281 1291
65. T. Murata, F. Ushikubi, T. Matsuoka, M. Hirata, A. Yamasaki, Y. Sugimoto, A. Ichikawa, Y. Aze, T. Tanaka, N. Yoshida, A. Ueno, S. Oh-ishi, and S. Narumiya Altered pain perception and inflammatory response in mice lacking prostacyclin receptor Nature 388 1997 678 682
66. K. Nakao, A. Murase, H. Ohshiro, T. Okumura, K. Taniguchi, Y. Murata, M. Masuda, T. Kato, Y. Okumura, and J. Takada CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties J. Pharmacol. Exp. Ther. 322 2007 686 694
67. T.A. Samad, K.A. Moore, A. Sapirstein, S. Billet, A. Allchorne, S. Poole, J.V. Bonventre, and C.J. Woolf Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity Nature 410 2001 471 475
68. F. Beiche, S. Scheuerer, K. Brune, G. Geisslinger, and M. Goppelt-Struebe Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation FEBS Lett. 390 1996 165 169
69. A. Inoue, K. Ikoma, N. Morioka, K. Kumagai, T. Hashimoto, I. Hide, and Y. Nakata Interleukin-1beta induces substance P release from primary afferent neurons through the cyclooxygenase-2 system J. Neurochem. 73 1999 2206 2213
70. T. Tonai, Y. Taketani, N. Ueda, T. Nishisho, Y. Ohmoto, Y. Sakata, M. Muraguchi, K. Wada, and S. Yamamoto Possible involvement of interleukin-1 in cyclooxygenase-2 induction after spinal cord injury in rats J. Neurochem. 72 1999 302 309
71. P. Patrignani, S. Tacconelli, A. Bruno, C. Sostres, and A. Lanas Managing the adverse effects of nonsteroidal anti-inflammatory drugs Expert. Rev. Clin. Pharmacol. 4 2011 605 621
72. C. Hawkey Non-steroidal anti-inflammatory drugs and peptic ulcers: facts and figures multiply, but do they add up? BMJ 300 1990 278 284
73. D. Henry, L.L. Lim, L.A. García Rodríguez, S. Perez Gutthann, J.L. Carson, M. Griffin, R. Savage, R. Logan, Y. Moride, C. Hawkey, S. Hill, and J.T. Fries Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis BMJ 312 1996 1563 1566
74. S. Hernandez-Diaz, and L.A. García Rodríguez Overview of epidemiological studies published in the nineties on the association between non-steroidal anti-inflammatory drugs and upper gastrointestinal bleed/perforation Arch. Intern. Med. 160 2000 2093 2099
75. T.J. Schnitzer, G.R. Burmester, E. Mysler, M.C. Hochberg, M. Doherty, E. Ehrsam, X. Gitton, G. Krammer, B. Mellein, P. Matchaba, A. Gimona, C.J. Hawkey CJ, and TARGET Study Group Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial Lancet 364 2004 665 674
76. L. Laine, E.S. Maller, C. Yu, H. Quan, and T. Simon Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2-selective inhibition: a double-blind trial Gastroenterology 127 2003 395 402
77. J. Shigeta, S. Takahashi, and S. Okabe Role of cyclooxygenase-2 in the healing of gastric ulcers in rats J. Pharmacol. Exp. Ther. 86 1998 1383 1390
78. A. Schmassmann, G. Zoidl, B.M. Peskar, B. Waser, D. Schmassmann-Suhijar, J.O. Gebbers, and J.C. Reubi Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice Am. J. Physiol. Gastrointest. Liver Physiol. 290 2006 G747 G756
79. H. Mizuno, C. Sakamoto, K. Matsuda, K. Wada, T. Uchida, H. Noguchi, T. Akamatsu, and M. Kasuga Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice Gastroenterology 112 1997 387 397
80. S. Takahashi, J. Shigeta, H. Inoue, T. Tanabe, and S. Okabe Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats Am. J. Physiol. 275 1998 G1137 G1145
81. A. Tanaka, H. Araki, Y. Komoike, S. Hase, and K. Takeuchi Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs J. Physiol. Paris 95 2001 21 27
82. D.J. Fitzgerald, L. Roy, F. Catella, and G.A. FitzGerald Platelet activation in unstable coronary disease N. Engl. J. Med. 315 1986 983 989
83. M. Vejar, G. Fragasso, D. Hackett, D.P. Lipkin, A. Maseri, G.V. Born, G. Ciabattoni, and C. Patrono Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina Thromb. Haemost. 63 1990 163 168
84. P.J. Koudstaal, G. Ciabattoni, J. van Gijn, H.K. Nieuwenhuis, P.G. de Groot, J.J. Sixma, and C. Patrono Increased thromboxane biosynthesis in patients with acute cerebral ischemia Stroke 24 1993 219 223
85. F. van Kooten, G. Ciabattoni, C. Patrono, P.I. Schmitz, J. van Gijn, and P.J. Koudstaal Evidence for episodic platelet activation in acute ischemic stroke Stroke 25 1994 278 281
86. Antithrombotic Trialists' Collaboration C. Baigent, L. Blackwell, R. Collins, J. Emberson, J. Godwin, R. Peto, J. Buring, C. Hennekens, P. Kearney, T. Meade, C. Patrono, M.C. Roncaglioni, and A. Zanchetti Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
87. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
88. C. Patrono Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? Eur. Heart J. 34 2013 3403 3411
89. M.G. Bousser, P. Amarenco, A. Chamorro, M. Fisher, I. Ford, K.M. Fox, M.G. Hennerici, H.P. Mattle, P.M. Rothwell, A. de Cordoüe, M.D. Fratacci PERFORM Study Investigators Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial Lancet 377 2011 2013 2022
90. Y. Yu, E. Ricciotti, R. Scalia, S.Y. Tang, G. Grant, Z. Yu, G. Landesberg, I. Crichton, W. Wu, E. Puré, C.D. Funk, and G.A. FitzGerald Vascular COX-2 modulates blood pressure and thrombosis in mice Sci. Transl. Med. 4 2012 (132ra54)
91. E. Ricciotti, Y. Yu, T. Grosser, and G.A. FitzGerald COX-2, the dominant source of prostacyclin Proc. Natl. Acad. Sci. U. S. A. 110 2013 E183
92. C. Patrono, and C. Baigent Nonsteroidal anti-inflammatory drugs and the heart Circulation 129 2014 907 916
93. Y. Yu, J. Stubbe, S. Ibrahim, W.L. Song, E.M. Smyth, C.D. Funk, and G.A. FitzGerald Cyclooxygenase-2-dependent prostacyclin formation and blood pressure homeostasis: targeted exchange of cyclooxygenase isoforms in mice Circ. Res. 106 2010 337 345
94. L. Hansson, A. Zanchetti, S.G. Carruthers, B. Dahlöf, D. Elmfeldt, S. Julius, J. Ménard, K.H. Rahn, H. Wedel, and S. Westerling Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal treatment (HOT) randomised trial. HOT Study Group Lancet 351 1998 1755 1762
95. D.A. Dixon, F.F. Blanco, A. Bruno, and P. Patrignani Mechanistic aspects of COX-2 expression in colorectal neoplasia Recent Results Cancer Res. 191 2013 7 37
96. R.N. DuBois, A. Radhika, B.S. Reddy, and A.J. Entingh Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors Gastroenterology 110 1996 1259 1262
97. X. Hao, A.E. Bishop, M. Wallace, H. Wang, T.C. Willcocks, J. Maclouf, J.M. Polak, S. Knight, and I.C. Talbot Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis J. Pathol. 187 1999 295 301
98. S.J. Shiff, and B. Rigas The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs) J. Exp. Med. 190 1999 445 450
99. D. Wang, and R.N. Dubois Eicosanoids and cancer Nat. Rev. Cancer 10 2010 181 193
100. D. Wang, and R.N. Dubois The role of COX-2 in intestinal inflammation and colorectal cancer Oncogene 29 2010 781 788
101. A. Bennett, and M. Del Tacca Proceedings: prostaglandins in human colonic carcinoma Gut 16 1975 409
102. B.M. Jaffe Prostaglandins and cancer: an update Prostaglandins 6 1974 453 461
103. B. Rigas, I.S. Goldman, and L. Levine Altered eicosanoid levels in human colon cancer J. Lab. Clin. Med. 122 1993 518 523
104. A. Ferrandez, S. Prescott, and R.W. Burt COX-2 and colorectal cancer Curr. Pharm. Des. 9 2003 2229 2251
105. M.J. Thun, E.J. Jacobs, and C. Patrono The role of aspirin in cancer prevention Nat. Rev. Clin. Oncol. 9 2012 259 267
106. C. Eberhart, R.J. Coffey, A. Radhika, F.M. Giardiello, S. Ferrenbach, and R.N. DuBois Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas Gastroenterology 107 1994 1183 1188
107. S.L. Kargman, G.P. O'Neill, P.J. Vickers, J.F. Evans, J.A. Mancini, and S. Jothy Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer Cancer Res. 55 1995 2556 2559
108. C.V. Rao, and B.S. Reddy NSAIDs and chemoprevention Curr. Cancer Drug Targets 4 2004 29 42
109. F.A. Sinicrope Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer Mol. Carcinog. 45 2006 447 454
110. D.A. Dixon, N.D. Tolley, K. Bemis-Standoli, M.L. Martinez, A.S. Weyrich, J.D. Morrow, S.M. Prescott, and G.A. Zimmerman Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling J. Clin. Invest. 116 2006 2727 2738
111. L.E. Young, S. Sanduja, K. Bemis-Standoli, E.A. Pena, R.L. Price, and D.A. Dixon The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis Gastroenterology 136 2009 1669 1679
112. D.A. Dixon, G.C. Balch, N. Kedersha, P. Anderson, G.A. Zimmerman, R.D. Beauchamp, and S.M. Prescott Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1 J. Exp. Med. 198 2003 475 481
113. D.A. Dixon, N.D. Tolley, P.H. King, L.B. Nabors, T.M. McIntyre, G.A. Zimmerman, and S.M. Prescott Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells J. Clin. Invest. 108 2001 1657 1665
114. J. Shao, H. Sheng, H. Inoue, J.D. Morrow, and R.N. DuBois Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells J. Biol. Chem. 275 2000 33951 33956
115. H. Sheng, J. Shao, D.A. Dixon, C.S. Williams, S.M. Prescott, R.N. DuBois, and R.D. Beauchamp Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA J. Biol. Chem. 275 2000 6628 6635
116. G. Steinbach, P.M. Lynch, R.K. Phillips, M.H. Wallace, E. Hawk, G.B. Gordon, N. Wakabayashi, B. Saunders, Y. Shen, T. Fujimura, L.K. Su, B. Levin, L. Godio, S. Patterson, M.A. Rodriguez-Bigas, S.L. Jester, K.L. King, M. Schumacher, J. Abbruzzese, R.N. DuBois, W.N. Hittelman, S. Zimmerman, J.W. Sherman, and G. Kelloff The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N. Engl. J. Med. 342 2000 1946 1952
117. M. Dovizio, T.J. Maier, S. Alberti, L. Di Francesco, E. Marcantoni, G. Münch, C.M. John, B. Suess, A. Sgambato, D. Steinhilber, and P. Patrignani Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced, overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells Mol. Pharmacol. 84 2013 25 40
118. A. Bruno, M. Dovizio, S. Tacconelli, and P. Patrignani Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract Best Pract. Res. Clin. Gastroenterol. 26 2012 e1 e13
119. P.M. Rothwell, M. Wilson, C.E. Elwin, B. Norrving, A. Algra, C.P. Warlow, and T.W. Meade Long-term effect of aspirin on colorectal cancer incidence and mortality: 20 year follow-up of five randomised trials Lancet 376 2010 1741 1750
120. M. Rothwell, F.G. Fowkes, J.F. Belch, H. Ogawa, C.P. Warlow, and T.W. Meade Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 2011 31 41
121. D. Stegner, S. Dütting, and B. Nieswandt Mechanistic explanation for platelet contribution to cancer metastasis Thromb. Res. 133 S2 2014 S149 S157
122. M. Korotkova, and P.J. Jakobsson Characterization of microsomal prostaglandin E synthase 1 inhibitors Basic Clin. Pharmacol. Toxicol. 114 2014 64 69
123. M. Wang, K. Ihida-Stansbury, D. Kothapalli, M.C. Tamby, Z. Yu, L. Chen, G. Grant, Y. Cheng, J.A. Lawson, R.K. Assoian, P.L. Jones, and G.A. FitzGerald Microsomal prostaglandin E2 synthase-1 modulates the response to vascular injury Circulation 123 2011 631 639